Ralliant (NYSE:RAL) Sets New 52-Week High – Time to Buy?

Shares of Ralliant Corporation (NYSE:RAL) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $62.95 and last traded at $61.69, with a volume of 26790 shares traded. The stock had previously closed at $61.55.

Analysts Set New Price Targets

RAL has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Barclays raised their target price on Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Citigroup raised their target price on Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Oppenheimer raised their target price on Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. Finally, Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a research note on Monday, April 13th. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $62.50.

Ralliant Stock Performance

The firm has a 50-day moving average price of $47.24 and a 200 day moving average price of $48.25. The firm has a market capitalization of $6.97 billion and a PE ratio of -5.69. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL) last announced its earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. The company had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The business’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Research analysts expect that Ralliant Corporation will post 2.64 earnings per share for the current year.

Ralliant Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be issued a $0.05 dividend. The ex-dividend date is Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s payout ratio is -1.83%.

Insider Transactions at Ralliant

In other Ralliant news, SVP Karen M. Bick sold 2,530 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $46.50, for a total transaction of $117,645.00. Following the sale, the senior vice president directly owned 42,652 shares in the company, valued at $1,983,318. This represents a 5.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Institutional Trading of Ralliant

Hedge funds have recently modified their holdings of the stock. Danske Bank A S purchased a new position in Ralliant in the fourth quarter valued at $25,000. Allworth Financial LP increased its holdings in Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares during the period. V Square Quantitative Management LLC acquired a new stake in Ralliant in the 4th quarter valued at about $26,000. Westfuller Advisors LLC purchased a new position in shares of Ralliant in the 3rd quarter valued at about $26,000. Finally, Palisade Asset Management LLC purchased a new position in shares of Ralliant in the 3rd quarter valued at about $26,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.